[HTML][HTML] Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model

K Haga, R Takai-Todaka, Y Matsumura, C Song… - PLoS …, 2021 - journals.plos.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the
disease COVID-19 can lead to serious symptoms, such as severe pneumonia, in the elderly …

[HTML][HTML] Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants

J Lu, Q Yin, R Pei, Q Zhang, Y Qu, Y Pan, L Sun, D Gao… - Virologica Sinica, 2022 - Elsevier
Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have constantly emerged, as the delta and omicron variants, which have developed …

[PDF][PDF] Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters

MS Piepenbrink, JG Park, FS Oladunni… - Cell Reports …, 2021 - cell.com
SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission
and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody …

Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice

H Zhang, Z Yang, J Xiang, Z Cui, J Liu, C Liu - BioRxiv, 2020 - biorxiv.org
Prevention of SARS-CoV-2 infection at the point of nasal entry is a novel strategy that has
the potential to help contain the ongoing pandemic. Using our proprietary technologies, we …

[PDF][PDF] A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model

J Kreye, SM Reincke, HC Kornau, E Sánchez-Sendin… - Cell, 2020 - cell.com
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019
(COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed …

[HTML][HTML] Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

S Halwe, A Kupke, K Vanshylla, F Liberta, H Gruell… - Viruses, 2021 - mdpi.com
Despite the recent availability of vaccines against severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …

[HTML][HTML] Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants

C Boonkrai, TS Cotrone, W Chaisuriyong… - Plos one, 2023 - journals.plos.org
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
currently the biggest healthcare issue worldwide. This study aimed to develop a monoclonal …

[HTML][HTML] A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters

AC Fagre, J Manhard, R Adams, M Eckley… - Frontiers in …, 2020 - frontiersin.org
The emergence of COVID-19 has led to a pandemic that has caused millions of cases of
disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir …

[PDF][PDF] Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

D Zhou, JFW Chan, B Zhou, R Zhou, S Li, S Shan… - Cell host & …, 2021 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst
in the upper respiratory portal for high transmissibility. To determine human neutralizing …

[HTML][HTML] Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on spike and provides antiviral protection through inhalation-based …

P Hermet, B Delache, C Herate, E Wolf, G Kivi… - PLoS …, 2023 - journals.plos.org
The COVID-19 pandemic represents a global challenge that has impacted and is expected
to continue to impact the lives and health of people across the world for the foreseeable …